Alveolar Soft Part Sarcoma

  • Murray F. Brennan
  • Cristina R. Antonescu
  • Robert G. Maki


Alveolar soft part sarcoma (ASPS) is a rare sarcoma that typically arises in the lower extremity in adolescents and young adults between 15 and 40 years of age. Distribution by age and site in adults is shown in Figs. 17.1 and 17.2 for all adult ASPS. In children, a number of cases arise from the tongue and orbit, where it can be confused to some degree with embryonal rhabdomyosarcoma. ASPS is extremely rare, even at referral centers, which have been hard pressed to identify more than one to two patients a year per center in published series [1–3]. It frequently presents with innumerable small, round metastatic lesions in the lungs and shows a very slow rate of progression, one reason for the late presentation of what is often a primary >10 cm in greatest dimension. Progression is typically slow, but ultimately taking the patient’s life after 10–15 years of metastatic disease. Brain metastases are a particular feature of ASPS, with an incidence at least thrice of that of other sarcomas in one series and documentation in other series [4–7].


Metastatic Disease Brain Metastasis Tyrosine Kinase Inhibitor Late Presentation Great Dimension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lieberman PH, Brennan MF, Kimmel M, et al. Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. Cancer. 1989;63(1):1–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Pennacchioli E, Fiore M, Collini P, et al. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. Ann Surg Oncol. 2010:17(12):3229–33.Google Scholar
  3. 3.
    Kayton ML, Meyers P, Wexler LH, et al. Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. J Pediatr Surg. 2006;41(1):187–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Haga Y, Kusaka G, Mori S, et al. A case of alveolar soft-part sarcoma with cerebral metastases. No To Shinkei. 1996;48(3):269–74.PubMedGoogle Scholar
  5. 5.
    Postovsky S, Ash S, Ramu IN, et al. Central nervous system involvement in children with sarcoma. Oncology. 2003;65(2):118–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Reichardt P, Lindner T, Pink D, et al. Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J Cancer. 2003;39(11):1511–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Pennacchioli E, Fiore M, Collini P, et al. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. Ann Surg Oncol. 2010;17(12):3229–33.PubMedCrossRefGoogle Scholar
  8. 8.
    Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20(1):48–57.PubMedCrossRefGoogle Scholar
  9. 9.
    Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001;159(1):179–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Ladanyi M, Antonescu CR, Drobnjak M, et al. The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. Am J Pathol. 2002;160(4):1215–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Kuriyama K, Todo S, Hibi S, et al. Alveolar soft part sarcoma with lung metastases. Response to interferon alpha-2a? Med Pediatr Oncol. 2001;37(5):482–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Bisogno G, Rosolen A, Carli M. Interferon alpha for alveolar soft part sarcoma. Pediatr Blood Cancer. 2005;44(7):687–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Gardner K, Leahy M, Alvarez-Gutierrez M, et al. Activity of the VEGFR/KIT tyrosine kinase inhibitor cediranib (AZD2171) in alveolar soft part sarcoma. Proc Connect Tissue Oncol Soc ( 2008;14:Abstr 34936
  14. 14.
    Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res. 2009;15(3):1096–104.PubMedCrossRefGoogle Scholar
  15. 15.
    Rekhi B, Ingle A, Agarwal M, et al. Alveolar soft part sarcoma ‘revisited’: clinicopathological review of 47 cases from a tertiary cancer referral centre, including immunohistochemical expression of TFE3 in 22 cases and 21 other tumours. Pathology. 2012;44(1):11–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Murray F. Brennan
    • 1
  • Cristina R. Antonescu
    • 2
  • Robert G. Maki
    • 3
  1. 1.International Center & Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of PathologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Departments of Medicine Pediatrics, and OrthopaedicsMount Sinai School of MedicineNew YorkUSA

Personalised recommendations